Vitamin D-deficiency rickets is biochemically characterized by a low-serum 25-hydroxy vitamin D (25OHD) level, normal- or low-serum calcium, low-serum phosphorous, elevated serum alkaline phosphatase, and increased parathyroid hormone (PTH). Vitamin D is solublized by intraluminal bile acids and is absorbed through the brush border of the intestinal enterocytes, mainly in the jejunum and ileum. Intestinal absorption of vitamin D is impaired in patients with intestinal, pancreatic, and hepatobiliary disorders and disorders of bile acid synthesis (BASD) or secretion.

BASD are a group of autosomal recessively inherited metabolic disorders that impair the hepatic synthesis of primary bile acids from cholesterol. Bile acids synthesized in the liver play a pivotal role in the absorption of fats and fat-soluble vitamins and in the elimination of cholesterol from the body \[[@B1], [@B2]\]. BASD present with disparate phenotypes, including cholestasis, failure to thrive (FTT), steatorrhea, hepatosplenomegaly, malabsorption of fats and fat-soluble vitamins in infants and children, and advanced liver disease in later life \[[@B1], [@B3], [@B4]\]. If undiagnosed, life-threatening complications, such as liver cirrhosis and eventually, liver failure, can occur.

We present a set of twins, presenting at 6-months of age, with refractory vitamin D-deficiency rickets and FTT caused by a BASD. Their cousins, who are affected by the same disorder, only manifested hepatobiliary abnormalities.

1. Case Report {#s1}
==============

A. Patients 1 and 2 {#s2}
-------------------

A 6-month-old girl of Hispanic origin presented to a regional hospital with respiratory syncytial virus bronchiolitis and hypocalcemia. Physical examination was substantial for open anterior fontanelle, widening of wrists, and prominent costochondral junctions. The patient had a body weight of 4 kg (less than the fifth percentile), serum calcium concentration of 7.7 mg/dL, serum phosphorous of 1.4 mg/dL, elevated PTH of 510 pg/mL, and undetectable 25OHD. Her twin sister was also evaluated. The twin sister also had FTT (weight 4.9 kg), hypocalcemia (serum calcium 7.7 mg/dL), hypophosphatemia (serum phosphorous 1.4 mg/dL), and undetectable 25OHD. Both had rachitic changes in the skeletal survey ([Fig. 1](#F1){ref-type="fig"}). They were born full term, small for gestational age, and with birth weights of 2.2 and 1.8 kg. They were fed mostly on "Similac Advance" formula, in addition to breast milk. There was no history of prolonged neonatal jaundice that required evaluation. There was no family history of rickets or metabolic bone diseases. Parents are nonconsanguineous, from Guatemala. The mother did not receive prenatal care and was not on any vitamin supplements during pregnancy.

![Rickets. X-Ray tibia of one of the twins. Arrows indicate metaphyseal fraying and cupping and loss of the zone of provisional calcification consistent with rickets at the upper and lower end of the tibia.](js.2018-00314f1){#F1}

Both children were initially started on oral calcium 100 mg/kg/day in four divided doses and ergocalciferol 800 IU daily. Subsequently, at the university hospital, the dose of vitamin D was increased to 2000 IU daily, because the infants continued to have persistent rickets ([Table 1](#T1){ref-type="table"}). Furthermore, the twins were not gaining appropriate weight or length, despite formula feeds and Stage 2 baby foods. Both patients had mild hypotonia and delayed motor development. Parents did not report acholic stools, jaundice, dark-colored urine, or pruritus. There was no hepatomegaly. Their transaminases were intermittently elevated, less than two times the upper limit of normal. As a result of persistent vitamin D-deficiency, the oral vitamin D doses were increased at each clinic visit.

###### 

Clinical Course of the Patients

  Age     Ca, mg/dL (8.7--9.8)   P, mg/dL (3.9--6.5)   Mg, mg/dL (1.6--2.6)                     Alk Phos, U/L (60--330)                   Albumin, g/dL (3.4--4.2)   25OHD, ng/mL                             1,25(OH)~2~D,  pg/mL                    PTH, pg/mL (15--65)   ALT, U/L (5--45)                                                       AST, U/L (20--60)   Total/Direct Bilirubin, mg/dL (0--1.1)                     Medications
  ------- ---------------------- --------------------- ---------------------------------------- ----------------------------------------- -------------------------- ---------------------------------------- --------------------------------------- --------------------- ---------------------------------------------------------------------- ------------------- ---------------------------------------------------------- --------------------------------
  6 Mo                                                                                                                                                                                                                                                                                                                                                                                                                            
  \#1     7.4                    1.4                   2.2                                      1810                                      4.3                        \<4[*^a^*](#t1n1){ref-type="table-fn"}   59[*^a^*](#t1n1){ref-type="table-fn"}   510                   81                                                                     61                  0.7                                                        Ergocalciferol 800 IU daily
  \#2     7.7                    1.3                   2.2                                      1316                                      4.3                        \<4[*^a^*](#t1n1){ref-type="table-fn"}                                           963                                                                                          67                  1.8                                                        Calcium carbonate 100 mg/kg/d
  8 Mo                                                                                                                                                                                                                                                                                                                                                                                                                            
  \#1     9.3                    4.3                   1.6                                      1388                                      5.3                        5[*^b^*](#t1n2){ref-type="table-fn"}                                             904                   73                                                                     57                  0.7                                                        Ergocalciferol 8000 IU daily
  \#2     9.7                    4.9                   1.6                                      1658                                      5.3                        6[*^b^*](#t1n2){ref-type="table-fn"}                                             714                   142                                                                    104                 1.9                                                        Calcium carbonate 100 mg/kg/d
  11 Mo                                                                                                                                                                                                                                                                                                                                                                                                                           
  \#1     10                     4.3                   4.7                                      6[*^b^*](#t1n2){ref-type="table-fn"}      535                        Ergocalciferol 16,000 IU daily                                                                                                                                                                                                                               
  \#2     9.5                    4.3                   4.2                                      7[*^b^*](#t1n2){ref-type="table-fn"}      425                        Calcium carbonate 100 mg/kg/d                                                                                                                                                                                                                                
  15 Mo                                                                                                                                                                                                                                                                                                                                                                                                                           
  \#1     8.1                    2.7                   2.2                                      799                                       4.2                        \<4[*^a^*](#t1n1){ref-type="table-fn"}   76[*^a^*](#t1n1){ref-type="table-fn"}   436                   50                                                                     49                  Ergocalciferol 50,000 IU daily, calcium carbonate          
  \#2     8.9                    4.3                   2.2                                      804                                       4.8                        \<4[*^a^*](#t1n1){ref-type="table-fn"}   71[*^a^*](#t1n1){ref-type="table-fn"}   574                   81                                                                     67                  Vitamin K 2.5 mg, ursodeoxycholic acid, vitamins A and E   
  16 Mo                                                                                                                                                                                                                                                                                                                                                                                                                           Ergocalciferol 50,000 IU daily
  \#1     9.6                    1172                  \<4[*^a^*](#t1n1){ref-type="table-fn"}   86[*^a^*](#t1n1){ref-type="table-fn"}                                58                                       63                                      1.5/1.1               Calcium carbonate                                                                                                                                     
  \#2     9.6                    804                   \<4[*^a^*](#t1n1){ref-type="table-fn"}   85[*^a^*](#t1n1){ref-type="table-fn"}     698                        70                                       70                                      1.3/0.9               Vitamin K 2.5 mg, ursodeoxycholic acid, vitamins A and E cholic acid                                                                                  
  18 Mo                                                                                                                                                                                                                                                                                                                                                                                                                           Cholic acid only
  \#1     10.0                   296                   4.2                                      \>96[*^b^*](#t1n2){ref-type="table-fn"}   58                         46                                       46                                      0.4                                                                                                                                                                         
  \#2     9.9                    289                   4.3                                      \>96[*^b^*](#t1n2){ref-type="table-fn"}   38                         61                                       60                                      0.4                                                                                                                                                                         
  19 Mo                                                                                                                                                                                                                                                                                                                                                                                                                           Cholic acid only
  \#1     10.2                   281                   4.6                                      \>96[*^b^*](#t1n2){ref-type="table-fn"}   38                         61                                       52                                      0.5                                                                                                                                                                         
  \#2     10.0                   296                   4.8                                      \>96[*^b^*](#t1n2){ref-type="table-fn"}   44                         65                                       42                                      0.9                                                                                                                                                                         
  3 Y                                                                                                                                                                                                                                                                                                                                                                                                                             Cholic acid only
  \#1     9.6                    5.1                   1.6                                      278                                       4.6                        41[*^a^*](#t1n1){ref-type="table-fn"}    74[*^a^*](#t1n1){ref-type="table-fn"}   38                    45                                                                     47                  0.7                                                        
  \#2     9.4                    5.1                   1.7                                      269                                       4.8                        41[*^a^*](#t1n1){ref-type="table-fn"}    66[*^a^*](#t1n1){ref-type="table-fn"}   55                    30                                                                     35                  0.6                                                        

Abbreviations: \#1 and \#2, Patients 1 and 2 (set of twins); 25OHD, 25-hydroxy vitamin D; 1,25(OH)~2~D, 1,25-dihydroxy vitamin D; Alk Phos, serum alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Ca, serum calcium; Mg, serum magnesium; P, serum phosphorus.

The 25OHD and 1,25(H)~2~D assays were obtained commercially (Quest Diagnostics Nichols Institute, San Juan Capistrano, CA), using liquid chromatography-tandem mass spectrometry (MS/MS) methodology.

The 25OHD was measured by the Abbott Architect Assay by chemiluminescent microparticle immunoassay through the hospital laboratory.

Given the severe FTT, refractory vitamin D-deficiency rickets unresponsive to massive doses of vitamin D and calcium, and mildly elevated liver enzymes, a hepatobiliary disorder was suspected. The twins had normal serum prealbumin, albumin, ammonia, gamma glutamyl transferase (GGT) levels, celiac panel, as well as MM *α*-1-phenotype, hepatitis B and C panels, lipid profile, and fecal elastase. Fecal fat and qualitative fat examination results were not available. The serum bilirubin increased slowly (see [Table 1](#T1){ref-type="table"}) in both infants, and by the age of 15 months, the twins developed scleral icterus and hepatomegaly. They reported feeding intolerance and acholic stools at that time. Both twins had delayed motor development and had not yet started walking. The laboratory evaluation revealed low-serum concentrations of fat-soluble vitamins \[vitamin A 16 μg/dL (20--43 μg/dL), vitamin E 0.2 mg/L (2.9--16.6 mg/L), and vitamin K1 \< 72 pg/mL (normal 80--160 pg/mL)\]. They also had elevated prothrombin time (PT; 17.8 and 17.6 seconds, respectively), partial thromboplastin time (42.0 and 43.1 seconds), and the international normalized ratio (INR; 1.4 in both). They had normal serum zinc, copper, and vitamin B12 concentrations. Abdominal ultrasound revealed mild hepatomegaly with the absence of focal hepatic lesions or intrahepatic biliary dilation. Treatment consisted of oral ursodeoxycholic acid (15 mg/kg/day), vitamin K 2.5 mg daily, and vitamins A and E, in addition to high doses of vitamin D (ergocalciferol 50,000 IU daily) and oral calcium (100 mg/kg/day).

Subsequent evaluations revealed normal serum bile acids analyzed by liquid chromatography. Fast atom bombardment ionization mass spectrometry (FAB-MS) revealed abnormal urine bile acid profile in both twins with the characteristic atypical bile acids that are the biomarkers for a 3*β*-hydroxy-*Δ*^5^-C~27~-steroid oxidoreductase (HSD3B7) deficiency ([Fig. 2](#F2){ref-type="fig"}). Plasma analysis by gas chromatography/MS revealed very low concentrations of cholic and chenodeoxycholic acid and high concentrations of 3*β*,7*α*-dihydroxy-5-cholenoic and 3*β*,7*α*,12*α*-trihydroxy-5-cholenoic acids. A neonatal and adult cholestasis sequencing panel (Emory Genetics Laboratory, Tucker, GA) identified previously unreported homozygous pathogenic variant nucleotide change at c.890delT. Both babies received treatment with cholic acid at a dose of 10 mg/kg/day at age 16 months, and within 3 months, serum aminotransferases, coagulopathy, and fat-soluble vitamin deficiencies resolved. Parents reported that the twins started walking within 1 month of starting cholic acid.

![FAB-MS. The negative ion mass spectrum was remarkable for the absence of the usual primary bile acid conjugates, and instead, ions of mass/charge (*m/z*) 453, 469, 485, 526, and 542 were dominant that correspond to the atypical sulfate and glycosulfate conjugates of the unsaturated bile acids and dihydroxy- and trihydroxy-cholenoic acids.](js.2018-00314f2){#F2}

Subsequent to the diagnosis of Patients 1 and 2 with HSD3B7 deficiency, information regarding two of their first cousins was obtained.

B. Patients 3 and 4 {#s3}
-------------------

Patient 3 presented with FTT, with weight below the first percentile, diarrhea, firm hepatomegaly, and prolonged PT at age 23 months. She had cholestasis and portal fibrosis on a liver biopsy with serum total bilirubin 1.8 mg/dL, direct bilirubin 1.2 mg/dL, GGT 19 U/L, alanine transaminase (ALT) 66 U/L, aspartate aminotransferase 65 U/L, PT 17 seconds, and INR 1.3. There was no evidence of rickets on a skeletal survey. Urine FAB-MS, performed at age 24 months, had findings consistent with HSD3B7 deficiency. She responded to treatment with cholic acid with weight gain and resolution of laboratory abnormalities. Patient 4 was a sibling of Patient 3 who was evaluated after Patient 3 was diagnosed. His weight was below the first percentile, ultrasound indicated hepatic steatosis, and he was found to have a total serum bilirubin of 1.0 mg/dL, direct bilirubin of 0.6 mg/dL, normal GGT, ALT of 120 U/L, PT of 17.2 seconds, and an INR of 1.3. He also responded well to treatment with cholic acid. These patients did not have hypotonia or developmental delays. At age 12 years, Patient 3 had a weight in the 50th percentile and Patient 4 in the 67th percentile.

2. Discussion {#s4}
=============

We describe a BASD in a set of twins presenting with refractory vitamin D-deficiency rickets with concomitant minimal clinical or biochemical features of cholestasis or history of prolonged neonatal hyperbilirubinemia or conjugated hyperbilirubinemia. Even though the motor delay and hypotonia can be seen in vitamin D-deficiency \[[@B5], [@B6]\], as a result of its known impact on muscle function, the refractory rickets not responding to mega doses of vitamin D \[[@B6]\] and persistent, severe FTT indicated gastrointestinal tract malabsorption or a hepatobiliary disorder. These cases illustrate a diagnostic conundrum as a result of the presence of trivial liver dysfunction and because the typical gastrointestinal workup was negative. The twins have a newly described mutation of a nucleotide change at c.890delT leading to a HSD3B7 deficiency, resulting in characteristic urinary and serum bile acid profiles. Mutation of the *HSD3B7* gene on the short arm of chromosome 16 (16p11.2) is the most prevalent type of the BASD thus far described \[[@B7]\]. Patients with BASD have not been reported to have small for gestational age \[[@B8]\] but can present with FTT in infancy as a result of fat malabsorption from cholestasis and chronic liver disease.

This defect impairs the conversion of 7*α*-hydroxycholesterol to 7*α*-hydroxy-4-cholesten-3-one in the pathway of bile acid synthesis from cholesterol \[[@B9]\]. Even though the serum bile acids are quantitatively normal, the bile acid intermediates, produced because of the blockade in the pathway, are cholestatic and believed hepatotoxic \[[@B10]\]. In the absence of normal primary bile acid synthesis, there is reduced bile flow, and these atypical bile acids lead to hepatic injury with cholestasis. Cholic acid suppresses the endogenous synthesis of the atypical 3*β*-hydroxy-*Δ*^5^ bile acids through feedback inhibition and facilitates bile flow and micellar solubilization of fats and fat-soluble vitamins \[[@B2]\].

Often beginning in infancy, these inherited mutations affect the hepatic synthesis of cholic acid and chenodeoxy cholic acid from cholesterol, leading to fat and fat-soluble vitamin malabsorption \[[@B7], [@B11]\]. The information regarding the cousins provides additional context for the hereditary nature of the disease and phenotypic spectrum of the condition. It is important to recognize that FTT and rickets may manifest before clinical features of the chronic liver disease in patients with BASD. With the failure of prompt recognition, patients can develop progressive cholestasis and cirrhosis from the accumulation of abnormal bile acid intermediaries. Although patients with the HSD3B7 deficiency present in the neonatal period, it may often be the cause of late-onset chronic cholestasis in older children and even adults \[[@B8], [@B12]\].

3. Conclusion {#s5}
=============

We report a case of an enzyme deficiency caused by a new mutation from a nucleotide change at c.890delT in the *HSD3B7* gene, causing HSD3B7 deficiency and leading to refractory vitamin D rickets. BASD are a rare group of disorders in which manifestations of the liver disease may be absent or inconspicuous yet should be considered as an underlying cause of some cases of refractory rickets and FTT.
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